Atzumi combines a proprietary advanced powder and device technology to simplify nasal delivery of dihydroergotamine for acute treatment of migraine.

ARS Pharmaceuticals has announced the availability of neffy (epinephrine nasal spray) 1mg in the US, providing a new option ...

A new nasal spray that uses a form of ketamine to treat stubborn depression will be added to the PBS, making treatment ...

The US Food and Drug Administration (FDA) has approved Atzumi, a 5.2 mg dihydroergotamine (DHE) nasal powder, for the acute ...

The Trump administration has proposed terminating a $56 million annual grant program that distributes naloxone, also known by ...

For five years, the clinical-stage pharmaceutical company has developed Enbumyst, a nasal spray intended to remove excess ...

Montgomery County is attributing a dramatic decline in drug deaths to efforts to prevent them, including availability of a ...

A new nasal spray, that’s chemically similar to Ketamine, is being added to the Pharmaceutical Benefits Scheme, for adults ...

An antidepressant containing a form of the drug ketamine has been added to the Pharmaceutical Benefits Scheme (PBS), making ...

A drug derived from ketamine will be added to the PBS, helping tens of thousands of Australians struggling with depression to ...